

(51) International Patent Classification:
C07K 16/24 (2006.01)(21) International Application Number:
PCT/EP2011/055253(22) International Filing Date:
5 April 2011 (05.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10380049.6 5 April 2010 (05.04.2010) EP(71) Applicants (for all designated States except US): **FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL HEBRON (VHIO)** [ES/ES]; Passeig Vall d'Hebron, 119-129, Edifici Matern-Infantil, Planta 14, E-08035 Barcelona (ES). **FUNDACIO PRIVADA INSTITUCIO CATALANA DE RECERCA I ESTUDIS AVANCATS (ICREA)** [ES/ES]; Passeig Lluís Companys, 23, E-08010 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SUAREZ, Joan Seoane** [ES/ES]; Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron (VHIO), E-08035 Barcelona (ES). **FOLGUEIRAS, Judit Anido** [ES/ES]; Fundacio Privada Institut D'investigacio Oncologica De Vall Hebron (VHIO), E-08035 Barcelona (ES). **BORDERIAS, Andrea Saez** [ES/ES]; Fundacio Privada Institut D'inves-

tigacio Oncologica De Vall Hebron (VHIO), E-08035 Barcelona (ES).

(74) Agents: **RENKEN, Joachim** et al.; (HOFFMANN · EITL), Arabellastrasse 4, 81925 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION

A



B




FIGURE 2

(57) Abstract: The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation.



-
- *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*